The friendly giant Google seems to be working on a lot more than search and marketing these days. Along with venturing into cell-phone and operating system territory it appears Google is also interested in the biotechnology sector. Google has begun investing in the start-up biotech company Adimab.
Tillman Gerngross, CEO of Adimab, has stated that ““Google is committing incredible resources to it. Incredible resources,” “The infrastructure alone is in the millions of dollars of raw computational power.” So what are they doing with all this computational power? They are running probability models trying to match antibodies to their respective receptors. This may not sound very exciting but a breakthrough in this field could lead to more effective drugs, lower research and development costs, and shorter development times. In short drug companies could develop antibody based medicine faster and cheaper. [xconomy]